A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Dec 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Flotetuzumab (Primary) ; Dexamethasone; Diphenhydramine; Diphenhydramine; Ibuprofen; Paracetamol; Ranitidine
Indications Blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukaemia; Haematological malignancies; Hairy cell leukaemia; Hodgkin's disease; Leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
Focus Adverse reactions

18 Dec 2023 Planned End Date changed from 15 Nov 2023 to 5 May 2026.
18 Dec 2023 Planned primary completion date changed from 15 Nov 2023 to 5 May 2026.
20 Sep 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com